What we do Alivus Life Sciences Ltd manufactures and markets Active Pharmaceutical Ingredients (APIs) globally, serving regulated and emerging markets with a focus on generics and complex molecules. |
Founded in 2,011 |
Market share Leading API manufacturer with diversified product portfolio and regulatory approvals across major markets; significant presence in regulated and emerging geographies. |
Problem solved Addresses global pharmaceutical supply by providing high-quality, cost-effective generic and complex active ingredients for various therapeutic areas. |
Top clients or who we serve Services global pharmaceutical companies including generics and innovator pharma in regulated markets like US, Europe, Japan, and emerging markets. B2B focused. |
Key management Dr. Yasir Rawjee (Managing Director & CEO) with strong pharma industry leadership. |
Our journey and innovations Started as Zorg Laboratories in 2011, acquired by Glenmark in 2018, renamed Alivus Life Sciences in 2025; expanded capacity via brownfield and greenfield projects; diversified into oncology and high-potency APIs. |
Where we operate Operations across India with exports to US, Europe, Japan, Latin America, and emerging markets worldwide. |
Top products or what we offer Generic APIs, Contract Development and Manufacturing (CDMO) services, oncology APIs, iron complexes, and specialized high-potency APIs. |
Top brands APIs for cardiovascular, CNS, anti-infective, diabetes, dermatology, urology, allergy sectors; 595 DMF/CEP filings globally. |
Raw materials needed Chemical intermediates and specialized raw chemicals necessary for API synthesis. |
Raw materials supplier Not specified; likely sourced globally from specialized chemical suppliers. |
Recurring vs cyclical contribution Revenue mostly recurring from long-term API supply contracts, with some cyclical elements from project-based CDMO work. |
Our industry position Among top Indian API manufacturers with strong regulatory compliance and growing CDMO segment expanding service offerings worldwide. |
Financial highlights FY25 revenue Rs2387 Cr, net profit Rs486 Cr; steady growth with 5.5% increase in total income and expanded margins. |
Geographical revenue split Domestic revenue Rs1152 Cr; international revenue Rs1235 Cr, balanced global exposure. |
Order book - |
Whats driving growth Capacity expansions, new product launches, stronger CDMO order inflows, and growth in regulated and emerging markets. |
Our future plans Brownfield expansions at Ankleshwar and Dahej; greenfield facility at Solapur; new oncology and high-potency APIs development. |
Our green promise Focus on reducing carbon footprint, process efficiency and adopting green chemistry techniques in manufacturing. |
Our people and values Employee stock option schemes, emphasis on diversity, safe work environment, and ethical corporate governance. |
Key challenges ahead Managing growth with capacity scaling, regulatory compliance risks, and competitive pressures in generics market. |
Interesting facts Formerly Glenmark Life Sciences, renamed in 2025; strong regulatory approvals including USFDA, EDQM, PMDA; acquired API business from Glenmark. |
Risks and strategy Mitigates risks via diversified markets, expanding product and capacity base, stringent quality controls, and R&D innovation. |
